William Pryor

Given current budget constraints, it is more important than even to use scarce resources wisely and I rise today to provide my colleagues with not only the numerous benefits associated with this innovative approach to educating our…

I believe the Senate needs to send a very strong signal that we will not tolerate sexual misconduct at our military academies. It is not only important for the cadets and their families but also for the Nation. There have been dozens of…

I simply respond by saying the generic companies cannot get the market because they cannot meet the requirements and the obstacles set forth in the Hatch substitute. It is that simple.

I have a letter from Donna Shalala, the Secretary of HHS, and I quote from the letter that has been distributed throughout the Senate this afternoon. Secretary Shalala says: It will be nearly impossible to meet the substantial investment…

This is indeed a classic case of the public interest versus the special interest. That is exactly what the issue is today on the floor. The Pryor-Brown-Chafee amendment closes a loophole that every expert in this field, from our Patent…

I would answer my colleague with reference to the law as it currently affects every industry but one. The court would determine damages on the basis of lost sales or profits, the length of time expired, and the multitude of other facts…

As I mentioned earlier, we are not in any way changing the URAA or GATT language. In fact, I look forward to the Senator from Pennsylvania offering language or an amendment to expedite the convoluted process contemplated in the substitute…

If, in the extremely unlikely event that a false claim of substantial investment is actually made by a generic competitor coming into the marketplace, the court may award damages in full, plus interest. If for some reason the court felt…

I regret I must correct the Senator from Pennsylvania. Both current law and our amendment allows for the sale of generic competitors, contemporaneous to a court determination of substantial investment. In other words, the term substantial…

That compensation is determined according to the language of the Uruguay Round Agreements Act, the GATT implementing legislation. On that point, let me reference the letter from the Department of Health and Human Services about the…

No, my friend and colleague is mistaken. The present law says that a generic competitor may come onto the marketplace, even though the court has not resolved the issue of whether they have made substantial investment. If, hypothetically…

That is absolutely true. The Uruguay Round Agreements Act clearly establishes it is the obligation of the generic competitor to prove a substantial investment before the court. It is the court which determines whether or not a substantial…